1 asset in POLE-Related Polyposis And Colorectal Cancer Syndrome

Therapeutic assets addressing POLE-Related Polyposis And Colorectal Cancer Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab POLE-Related Polyposis And Colorectal Cancer Syndrome	Rutgers, The State University of New Jersey	P2	CCC (53)